- Home
- ACXP vs FAAS Comparison
ACXP vs FAAS Comparison
Compare ACXP & FAAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- FAAS
- Stock Information
- Founded
- ACXP 2017
- FAAS 2021
- Country
- ACXP United States
- FAAS Indonesia
- Employees
- ACXP N/A
- FAAS N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- FAAS
- Sector
- ACXP Health Care
- FAAS
- Exchange
- ACXP Nasdaq
- FAAS NYSE
- Market Cap
- ACXP 8.4M
- FAAS 48.2M
- IPO Year
- ACXP 2021
- FAAS N/A
- Fundamental
- Price
- ACXP $0.50
- FAAS $0.46
- Analyst Decision
- ACXP Strong Buy
- FAAS
- Analyst Count
- ACXP 2
- FAAS 0
- Target Price
- ACXP $10.00
- FAAS N/A
- AVG Volume (30 Days)
- ACXP 18.6M
- FAAS 1.8M
- Earning Date
- ACXP 08-08-2025
- FAAS 01-01-0001
- Dividend Yield
- ACXP N/A
- FAAS N/A
- EPS Growth
- ACXP N/A
- FAAS N/A
- EPS
- ACXP N/A
- FAAS N/A
- Revenue
- ACXP N/A
- FAAS $57,730,593.00
- Revenue This Year
- ACXP N/A
- FAAS N/A
- Revenue Next Year
- ACXP N/A
- FAAS N/A
- P/E Ratio
- ACXP N/A
- FAAS N/A
- Revenue Growth
- ACXP N/A
- FAAS 38.16
- 52 Week Low
- ACXP $0.30
- FAAS $0.16
- 52 Week High
- ACXP $3.33
- FAAS $5.85
- Technical
- Relative Strength Index (RSI)
- ACXP 52.07
- FAAS 41.58
- Support Level
- ACXP $0.45
- FAAS $0.43
- Resistance Level
- ACXP $0.52
- FAAS $0.60
- Average True Range (ATR)
- ACXP 0.08
- FAAS 0.06
- MACD
- ACXP -0.01
- FAAS -0.02
- Stochastic Oscillator
- ACXP 20.83
- FAAS 15.59
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.